5171S-11: S0905 mesothelioma

SWOG 0905: Randomized Phase II Study of Cediranib (NSC #732208) Versus Placebo in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Malignant Pleural Mesothelioma

Type of Study
Cancer (Oncology) - Lung
Swedish Cancer Institute
Short Description

Purpose: This randomized phase II trial is studying the side effects and best dose of cediranib maleate when given together with pemetrexed disodium and cisplatin and tp see how well it works in treating patients with malignant pleural mesothelioma.

Open to Enrollment
Principal Investigator
Gary Goodman, M.D.
Eligibility Notes
  • Histologically or cytologically confirmed malignant pleural mesothelioma
    • Not planning to undergo surgical resection
  • Zubrod performance status 0-2
  • Must be able to swallow oral medications
  • No mean QTc > 500 msec (with Bazett correction) by ECG or other significant ECG abnormality
  • No NYHA class III-IV congestive heart failure
  • No prior systemic therapy (chemotherapy or other biological therapy) for unresectable malignant pleural mesothelioma
    • Prior systemic chemotherapy or biologic therapy as neoadjuvant or adjuvant therapy allowed provided disease has recurred and systemic therapy was completed > 6 months before study entry
  • At least 28 days since prior surgery (e.g., pleurectomy, pleurodeses, thoracic or other major surgeries) and recovered
  • At least 28 days since prior radiotherapy and recovered
More Info Link
Additional information about the study summary and eligibility criteria may be viewed on the U.S. National Institutes of Health (NIH) website.
(206) 215-3086